RENEW-MDD-3NCT07928245
A Study of Brenipatide in Participants With Major Depressive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Study sites: 75 to 76
- Start date changed from estimate of Nov 2026 to Nov 10, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS-9) Score
Timeframe: Baseline, Week 10
Secondary (4)
Change from Baseline in Hamilton Depression Rating Scale Score
Change from Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score
Achievement of Body Weight Reduction ≥5% in Participants with a Baseline Body Mass Index (BMI) ≥25 kg/m²
Number of Participants with Treatment-Emergent Anti-Drug Antibodies (ADA)
Arms and interventions
BrenipatideExperimental
Brenipatide administered subcutaneously (SC) + standard of care (SoC) anti-depressant
PlaceboPlacebo comparator
Placebo administered SC + SoC anti-depressant
Drugs: Brenipatide, Placebo
Sites
76 sites in 8 countries
United States 35, Poland 10, Romania 8, Spain 7, Bulgaria 5, Netherlands 5, United Kingdom 4, Hungary 2